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THE USE OF ASSISTED AUTOGENIC DRAINAGE IN CHILDREN WITH CYSTIC FIBROSIS, A PILOT 1 
RANDOMIZED CONTROLLED STUDY. 2 
ABSTRACT 3 
Background: Airway clearance therapy (ACT) is standard practice to promote pulmonary mucus 4 
clearance in children with cystic fibrosis (CF). However, the efficacy of assisted autogenic drainage 5 
(AAD) in children has not been studied. 6 
Objectives: To pilot a home-based randomized controlled trial (RCT) to compare the effects of AAD to 7 
standard ACT in children with CF aged one to eight years.  8 
Methods: Children with CF, aged one to eight years, were randomly assigned into intervention (AAD) 9 
or control (standard ACT) groups. The ACTs were taught to parents and children, to perform twice 10 
daily for a year. Primary outcome measures were number of hospitalizations, days of hospitalization, 11 
exacerbations and days of antibiotic therapy in one year. Secondary outcome measures included 12 
spirometry, and adherence assessed on every visit (through calendar and sticker system); parental 13 
proxy health related quality of life score (EQ-5D-Y), current clinical status (CF Clinical Score), weight-, 14 
height-, and BMI-for-age z-scores assessed at baseline and after one year; and preference of ACT and 15 
mortality rates were assessed at the end of the study. At the end of the study, a self-designed one on 16 
one subjective semi-structured interview with the parent(s)/caregiver(s) regarding physiotherapy 17 
management was conducted. 18 
Results: Of 36 children screened for inclusion, 16 were enrolled. Seven were randomly allocated to 19 
the control group (median [IQR] age 5.7 [3.0-6.0] years, four male and three female), and nine to the 20 
intervention group (median [IQR] age 5.8 [5.5-6.6] years, five male and four female). There were no 21 
significant between-group differences, however number of exacerbations revealed medium (Cohen’s 22 
d=0.55) effect sizes, favoring the intervention group. Although no significant improvements were 23 
 2 
 
seen within the intervention group, large effect sizes were found for the CF subjective and total 24 
clinical scores; and health related quality of life (Cohen’s d= 1.07, d= 0.87, and d= 0.86 respectively). 25 
This pilot study identified a number of concerns, mainly poor adherence to home-therapy in both 26 
arms of the study, and no participant in the intervention group solely performing AAD as per pre-set 27 
methodology, limiting interpretation of results. 28 
Conclusion: There is a need for confirmatory, adequately powered trials to evaluate safety and 29 
efficacy of AAD in children with CF. Future research needs to also consider measures to ensure better 30 
adherence to ACT. 31 
Trial registry: PACTR201501001016415 32 
Keywords: Airway Clearance Therapy, Assisted Autogenic Drainage, Cystic Fibrosis, Pediatrics 33 
34 
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INTRODUCTION  35 
Cystic fibrosis (CF), an autosomal recessive hereditary disease, affects all exocrine glands in the body, 36 
resulting in an altered airway environment leading to a vicious cycle of reduced mucociliary clearance 37 
secretion retention, airway obstruction, secondary chest infections and inflammation; and can result 38 
in irreversible lung damage (bronchiectasis) and respiratory failure [1,2]. Airway clearance therapy 39 
(ACT) has been shown to have positive effects on pulmonary mucus clearance in children with CF [3], 40 
and has been recommended by current guidelines for the management of CF [4,5]. However, the 41 
majority of studies investigating ACT in children with CF included children older than six years of age, 42 
with very few studies including infants and young children. In children under eight years of age, 43 
assisted autogenic drainage (AAD), a modified form of autogenic drainage (AD), may be used as it can 44 
be performed passively or active assisted [6]. This technique uses breathing at three different lung 45 
volumes; applying the principle of shear forces by producing optimal airflow in the small airways to 46 
remove secretions from peripheral to central airways, thereby theoretically preventing collapse of 47 
the small airways [7]. However, as most young patients cannot independently change the lung 48 
volumes towards the desired level, the physiotherapist manually alters the levels of breathing by 49 
applying graded pressure to the chest wall [6]. No gastro-esophageal reflux or other complications 50 
have been associated with AAD [8]. 51 
As the relative utility and superiority of individual ACTs in children younger than eight years of age is 52 
unknown, development of evidence-based information is a priority for this group of children. No 53 
randomized controlled trials (RCTs) have been published on AD or AAD in children with CF [9]. 54 
Therefore, this pragmatic study aimed to pilot a home-based RCT, to compare the effects of AAD to 55 
standard ACT in children with CF aged one to eight years. 56 
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METHODOLOGY 57 
Study design 58 
A single blinded (outcome assessor and data analyst blinded to allocation), pragmatic RCT was 59 
conducted at a multidisciplinary pediatric outpatient CF clinic. Treatment consisted of a taught 60 
home-program, executed by the parents who underwent training by the clinic’s physiotherapist (see 61 
Supplement 1 for training information). The study ran from 15 January 2015 until 30 September 62 
2016. 63 
This study aimed to enroll 30 children to be randomly assigned (1:1 ratio) to the intervention (n=15) 64 
or control (n=15) group (see Figure 1). Sample size was determined based on the estimated patient 65 
population, between one and eight years of age, attending the clinic (personal communication with 66 
CF clinic staff).  67 
Subjects 68 
Children diagnosed with CF, confirmed by two positive sweat tests and/or genotype analysis, 69 
between the age of one and eight years, who were followed up at the CF clinic, were considered for 70 
inclusion in the study. Exclusion criteria were: awaiting a lung transplant, severe scoliosis or kyphosis, 71 
osteoporosis, recent history (<six months) of pneumothorax or thoracic/abdominal surgery; 72 
emphysema or active sarcoidosis, premature birth (≤30 weeks), on anti-tuberculosis treatment, 73 
untreated/uncontrolled asthma, or known to be non-compliant to physiotherapy treatment prior to 74 
recruitment. 75 
Outcome measures 76 
This study’s primary outcome measures were number of hospitalizations, days of hospitalization, 77 
exacerbations and days of antibiotic therapy during one year. The secondary outcome measures 78 
were: spirometry and adherence, documented with a self-designed calendar and sticker system, 79 
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which was reviewed at each follow up visit (determined at the physician’s discretion, often 80 
performed quarterly); parental proxy health related quality of life score (HRQOL) by the EuroQol- five 81 
dimensions youth version (EQ-5D-Y), validated for the South African context and valid for children 82 
with CF [10,11]; current clinical status by the CF clinical score (CFCS), validated in a pediatric 83 
population [12]; weight-, height-, and BMI-for-age z-scores at baseline and end of study; preference 84 
of ACT (AAD versus standard ACT), using an adapted version of a standardized questionnaire 85 
designed by Jarad et al. (2010) [13] at first follow up and at the end of the study; and mortality rate 86 
at the end of the study period. 87 
Interventions 88 
Standard treatment, consisting of manual techniques (modified postural drainage (PD), percussion 89 
and vibration) and/or positive expiratory pressure (PEP) therapy or Flutter device and/or 90 
components of the active cycle of breathing technique (ACBT), was given to children in the control 91 
group, according to age, ability and preference[14]. The intervention group received AAD, performed 92 
in an upright position, standardizing the treatment position and optimizing use of the diaphragm, 93 
improving ventilation and influencing fatigue in infants and young children [6,15]. The caregiver 94 
manually increased the expiratory flow velocity and prolonged expiration towards residual volume by 95 
placing the hands on the child’s chest and gently following the breathing of the child while lowering 96 
thoracic expansion [6]. 97 
In this home-based study, treatments were meant to be performed twice daily. Duration of the 98 
treatments varied between five to 30 minutes, depending on the child’s tolerance (parents were 99 
educated on how to identify signs of respiratory distress, hypoxemia and infection). Parents were 100 
asked to carry out the intervention every day around the same time, once in the morning and once in 101 
the afternoon or evening.  102 
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Procedure 103 
Institutional ethical approval (HREC 648/2013) and approval from the medical superintendent at the 104 
research site was obtained. Participants were recruited during the weekly CF-clinic, over a 20 month 105 
time period. Eligibility of children was determined by screening the patients’ medical files. Written 106 
informed consent was obtained from the parent(s) and assent was obtained from children older than 107 
five years of age. An overview of the study procedure can be found in Supplementary file 3. All 108 
participants went through the same procedure unless otherwise indicated in Supplementary file 3. 109 
At the first follow up visit, approximately three months after recruitment, it became evident that 110 
compliance to a daily diary (indicating when, for how long, and which ACTs were given; and the 111 
reason(s) for terminating the intervention) was poor. Therefore, parents and patients were asked to 112 
adhere to a self-designed monthly calendar and sticker system. For each completed treatment, the 113 
child placed a sticker on the calendar. At each CF-clinic visit (quarterly for most participants), parents 114 
were asked to hand in their calendar for data storage and to assess adherence to treatment. If 115 
adherence was poor (determined by the clinic physiotherapist), the importance of ACT was 116 
emphasized and the parents counselled appropriately. Calendars were returned, approximately 117 
every three months, for the majority of participants. 118 
After one year follow up, the CF clinic’s social worker, who was blinded to group allocation and had 119 
an established rapport with clinic patients, conducted a self-designed one on one semi-structured 120 
interview with the parent(s)/caregiver(s) regarding physiotherapy management. Quantitative 121 
information was collected regarding the technique(s) used in the past year, duration and frequency 122 
of each technique; and qualitative information regarding the likes and dislikes of the different 123 
techniques used, with reasons for failure to perform technique(s) twice per day during the study 124 
period. This end of study interview was added to the protocol to obtain impartial, and honest 125 
reflection on adherence to the ACT interventions during the study period, and to gain insights into 126 
reasons for noncompliance, and preference. The interview answers were recorded in writing by the 127 
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social worker. No identifying information was available on the documents. It was emphasized that 128 
the information provided to the social worker would be used for research purposes only and not for 129 
patient management. 130 
Data-analysis 131 
All data were entered into an Excel spread sheet and analyzed with Statistica (Version 12, StatSoft 132 
Inc, Tulsa USA). An intention-to-treat analysis was performed. As the majority of data were skewed 133 
(based on the Lilliefors test) and the sample size was small, non-parametric tests were performed. 134 
Comparison between the control group and intervention groups on dichotomous data were done 135 
using the chi square test and Fisher exact or Yates correction; and numeric outcome parameters 136 
were analyzed using the Mann-Whitney U test. Effect size was calculated for outcome measures 137 
which showed, on initial univariate analysis, to have either a significant difference or a trend towards 138 
significant between-groups differences. The r value was calculated with the formula r= z/√N and 139 
converted into a Cohen’s d value by using the formula d= 2r/√(1-r2) [16]. Interpretation of the effect 140 
size was based on Cohen’s guidelines for small (d= 0.2), medium (d= 0.5) and large (d= 0.8) effect 141 
sizes [17]. Within group analysis was done by using the Wilcoxon matched pairs test. Quantitative 142 
results from the interview were presented as number of participants, frequencies of performed 143 
techniques and median (IQR) of duration of performed techniques. The qualitative information 144 
regarding likes and dislikes of the different techniques as well as the reasons for failure to perform 145 
technique(s) twice per day during the study period, was analyzed by identifying common themes or 146 
statements. 147 
RESULTS 148 
Subjects 149 
A total of 36 children, between the age of one and eight years, were screened. Nineteen children 150 
were excluded prior to enrolment due to various reasons (Supplementary file 3). One child, allocated 151 
 8 
 
to the control group, was excluded post-enrolment as the diagnosis of CF was questioned by the 152 
attending physician. The other participants all had a clear, confirmed diagnosis of CF. Therefore, 16 153 
participants were included in the study (median [IQR] 5.8 [4.3-6.3] years), nine in the intervention 154 
group and seven in the control group. All participants completed the one-year clinical trial, with no 155 
loss to follow up. Baseline characteristics of participants were similar between groups (Table 1). 156 
Results between groups at 12 months 157 
No significant differences were seen between the intervention and control group for any of the 158 
outcome measures (Table 2 and Supplementary file 2). However, calculation of the effect sizes 159 
revealed a medium effect size for ‘number of exacerbations during one year’ (d= 0.55), with fewer 160 
exacerbation during one year in the intervention group; and a small to medium effect size for ‘days 161 
on antibiotic therapy during one year’ (d= 0.48), for fewer days on antibiotic therapy in the 162 
intervention group.  163 
Due to the small number of participants (n= 2 in the control and 3 in the intervention group) who 164 
performed acceptable lung function tests [based on the quality criteria set by the ATS/ERS [18]], no 165 
statistical analyses were performed for this outcome measure.  166 
Results within groups 167 
There were no significant changes between baseline and end of study for any of the outcome 168 
measures in either group (Supplementary file 2). However, large effect sizes for EQ-5D-Y visual 169 
analogue scale score, and CFCS subjective subtotal and total scores were observed in favor of the 170 
intervention group (d= 1.07, d= 0.87, and d= 0.86 respectively). 171 
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Subjective questionnaire for preference and interview for adherence 172 
After one month 173 
Seven of the nine participants in the intervention group completed a written questionnaire with 174 
regards to their experience and preference of AAD compared to their ACT regime prior to the study 175 
(adapted from Jarad et al. 2010 [13]). Although AAD was not experienced as worse than the 176 
previously used ACTs for most aspects of the questionnaire, four of the seven participants would 177 
prefer to return to their previously used ACT. Participants remained in their allocated study arm 178 
throughout the entire study period, however, these participants were given additional information 179 
on the potential benefits of the technique and the clinic therapist had a discussion with participants 180 
regarding difficulties of administering the technique. The two participants who would prefer to use 181 
AAD instead of their previous ACT indicated that AAD was similar or better on all aspects of the 182 
questionnaire. One participant would prefer to combine AAD with their previous ACT. 183 
End of study interview 184 
An overview of the techniques used and duration can be found in Supplementary files 2 and 3. The 185 
themes regarding likes and dislikes per technique are presented in Table 3. 186 
For both groups, percussions and active play were the most preferred techniques during the study 187 
period, as they were performed most often, had most likes and least dislikes. 188 
Intervention group 189 
Two participants were not interviewed at the end of the study, as their primary caregivers were not 190 
present at the visit. Therefore, only information on seven of the nine participants in the intervention 191 
group is presented.  192 
Four of the seven participants used AAD during the trial. The other three reported not having used 193 
AAD throughout the study period. Furthermore, each of the following techniques was used by one 194 
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participant: Flutter, vibrations, ACBT, and blowing water; and five of the participants used additional 195 
percussions and active play. 196 
Non-adherence to AAD was due to the following themes: time consuming treatment regime (n=3) 197 
and the child resisting treatment (n=2). One participant indicated that there was no reason for non-198 
adherence, and one participant declined to answer this question. 199 
Control group 200 
In the control group, only three of the seven participants performed twice daily ACT. Techniques 201 
performed by participants in the control group during the study period were percussions (n=7), 202 
Flutter (n=2), vibrations (n=2) and ACBT (n=1). Further, six were engaged in active play/exercise 203 
during the day. 204 
Themes for non-adherence in this group were: time consuming treatment regime (n=3), child not 205 
being productive/ill (n=2), child vomits after treatment (n=1). Three participants did not provide a 206 
reason for non-adherence. 207 
DISCUSSION 208 
This study did not reveal any significant differences between the intervention (AAD) and control 209 
group (standard ACT) for any of its primary and secondary outcome measures. Due to the small 210 
number of participants, who poorly adhered to therapy prescription, no conclusions can be made 211 
regarding the effectiveness of AAD in children with CF aged one to eight years. However, interesting 212 
insights were gained with regards to the outcome measures and the methodology. This can be used 213 
to inform the development of future protocols, which could entail multi-center trials to increase 214 
sample size.  215 
As no literature is available on AAD in patients with CF, no comparison can be made with the current 216 
study’s results. Although several studies have been published on the use of AD in children with CF, 217 
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only one study by McIlwaine et al. [19], solely focused on children (aged 12-18 years), comparing AD 218 
with PD and percussions performed twice daily, in a two year long term home-based randomized 219 
cross-over study [19]. The other studies failed to report separate data for adults and children, for 220 
which they cannot be compared to the current study’s results. 221 
The primary outcome measure ‘number of hospitalizations in one year’ was not different between 222 
the two groups. This is in line with the results found in a study by McIlwaine et al [19]. Although the 223 
current study’s other primary outcome measure, ‘number of exacerbations during one year’, was not 224 
reported by McIlwaine et al.; they did note that more hospitalizations for pulmonary exacerbations 225 
were required for participants in the PD with percussions arm of the study, compared to the AD arm 226 
[19]. A small to medium effect size of fewer days on antibiotic therapy in the intervention group was 227 
found in the current study, which could suggest that AAD might clear infectious secretions from the 228 
lungs, therefore influencing antibiotic need. However other factors might influence antibiotic usage, 229 
such as bacterial load and type, manner of antibiotics administration and whether antibiotics were 230 
prescribed for long- or short- term use [20]. Therefore, trials with larger sample sizes are required to 231 
confirm results. 232 
No significant differences between groups for the current study’s secondary outcome measures were 233 
found. Although, spirometry, in particularly forced expiratory volume in one second (FEV1), is often 234 
recommended for monitoring disease progression in patients with CF [5,21]; improvements in CF 235 
management impact the value of FEV1 in monitoring disease progression [22].  Therefore, spirometry 236 
might not be the best outcome measure to use in future research studies. Furthermore, parents 237 
scored the current health of their children high on the EQ-5D-Y visual analogue scale (medians 238 
>85/100). This could be a result of the chronic nature of the disease, for which coping mechanisms 239 
might have led to adaptations in lifestyle and disease perceptions [10]. No comparison could be 240 
made with other studies on AD in the CF population. However, as patients with CF face many 241 
challenges throughout their life, assessment of HRQOL is important in this population [23]. Future 242 
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research could investigate the use of the Pediatric Quality of Life Questionnaire for children from the 243 
age of five years or the Cystic Fibrosis Questionnaire for children six years and older [24,25].  The 244 
current study also used the CFCS, which has not been reported in other studies in the CF population. 245 
Although there were large effect sizes for subjective and total CFCS scores within the intervention 246 
group in the current study, CFCS might not be the most appropriate outcome measure for a one year 247 
intervention as it was developed to assess the patient’s current clinical status [12,26].  The CFCS 248 
could be used on a more routine basis, e.g. during each follow up visit, to assess more objectively the 249 
presence of an exacerbation and the need for hospitalization. 250 
Mortality was not included as an outcome measure in any of the studies on AD in patients with CF, 251 
for which no comparison could be made. However, due to the young age included in the current 252 
study, mortality rate might not have been an appropriate outcome measure as mortality at such a 253 
young age is uncommon. Although not an intended outcome measure, no adverse events were 254 
reported in either arm of the current study. 255 
Finally, a preference for standard ACTs rather than AAD in the participants in the intervention group 256 
after one month in the study was revealed. This is in contrast with the study by McIlwaine et al, 257 
where 10 of the 17 participants did not want to return to PD with percussions after completion of the 258 
AD arm of the study [19]. This discrepancy between studies could be due to the difference in 259 
application of AD and AAD, as AD can be performed independently at any time of the day [7]. 260 
However, AAD is a passive/assisted technique which requires the caregiver to actively participate in 261 
applying the technique [6,27]. Two of the four caregivers who reported to use AAD at the end of the 262 
study period did mention that AAD was difficult to administer. AAD might therefore require more 263 
training of the caregiver, similar to AD, where the patient also requires multiple training session 264 
before effectively being able to apply the technique [28]. Although, the training of caregivers was 265 
performed in a standardized manner, done by the same therapist, with insurance of skill acquisition 266 
by demonstration and monitored every follow up to prevent change in the performance throughout 267 
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the study [29,30]; one session with three monthly follow up might not be sufficient to master and 268 
monitor this more complex technique. For future research, a more intense and regular training 269 
program might be needed to train the caregivers in applying AAD. Furthermore, in future studies, it is 270 
important to ensure buy-in from participants and parents, as well as monitor adherence to treatment 271 
protocol more in depth [29,30]. The use of a RCT study design might not be feasible in long-term ACT 272 
research, for which other designs should be considered to eliminate the post-randomization drop out 273 
[22]. Integration of AAD in the ACT toolkit from an early age could also be beneficial, as caregivers 274 
and children get used to the technique and be more comfortable in its application.  275 
Although standard ACTs were preferred to AAD, the adherence to these techniques was also poor. 276 
Studies on adherence to ACT and general medical treatment in children with CF reported an overall 277 
poor adherence to therapy (<50%)[31]. Factors influencing treatment adherence of children with CF 278 
and their caregivers include: socio-economic status (with maternal education and income higher than 279 
$50 000 identified as positive influencers for adherence); mental health (depression and anxiety, in 280 
both the child and the caregiver, negatively influencing treatment adherence); family relationships 281 
(supportive parents and a good child-parent relationship positively influencing adherence); time-282 
consuming therapy; and understanding of the disease progression and necessity of therapy[32–35]. 283 
In the current study, the main reason for non-adherence to ACT was the time-consuming nature of 284 
the intervention. Adherence to the original daily diary monitoring tools was also poor, for which it 285 
was changed to a calendar and sticker system. An end of study subjective interview was added to the 286 
protocol to further investigate participants’ adherence to ACT. However, this method of data 287 
gathering is not objective (self-reported adherence is found to be higher than objectively measured 288 
adherence)[36], and the current study failed to audio recorded and transcribed the interviews, nor 289 
were the qualitative information analyzed based on a framework. This could have limited the 290 
interpretability of the results, and the adherence rates provided in this current study cannot be used 291 
for generalization to a broader population. However, if self-reported treatment adherence is higher 292 
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than the actual adherence, the rates of adherence to twice daily ACTs in the current study are 293 
worrisome; highlighting the need for the use of an objective adherence monitoring tool to objectively 294 
quantify the problem in future studies. Several options have been reported in literature, such as daily 295 
telephone calls and electronic devices to monitor adherence [32,36,37]. However, these are not 296 
always feasible due to high cost and time constraints. Therefore, cost effective methods of 297 
adherence follow-up, monitoring adherence more frequently, from early in the study, should be 298 
explored, such as SMS, email, apps or online messaging.  299 
This study is the first pilot RCT on the use of AAD in children with CF. The results of this study add to 300 
the body of knowledge on AAD as an ACT in this population. This pilot study identified that AAD 301 
might be a useful technique to add to the airway clearance ‘toolbox’ for children with CF as no 302 
adverse events were reported and a small to medium effect size for number of days on antibiotic 303 
therapy was found, benefiting the intervention group. However, a number of concerns were also 304 
identified, mainly poor adherence to home-therapy and no participant in the intervention group 305 
solely performing AAD as per pre-set methodology, limiting interpretation of results and feasibility of 306 
conducting a full-scale long-term RCT in this population. The pre-specified sample of 30 participants 307 
could not be enrolled due to the limited availability of eligible participants at the CF clinic.  308 
CONCLUSION 309 
Conclusions cannot be made regarding the effectiveness and safety of AAD in children with CF due to 310 
the small sample size included in this study and the lack of adherence to the prescribed intervention. 311 
Further research is needed to investigate the usefulness of AAD in children of this population and to 312 
tackle issues related to treatment adherence.  313 
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TABLE 1. BASELINE CHARACTERISTICS OF PARTICIPANTS 
 
 
 
 
  
Characteristic Control group, n= 7 Intervention group, n= 9 p-value 
Gender, Male (n) 4 5 p= 0.671 
Age (years), median (IQRa) 5.7  
(3.0-6.0) 
5.8  
(5.5-6.6) 
p= 0.266 
Age diagnosis (months), median (IQRa) 3.0 
(0.0-6.0) 
3.0 
(1.0-6.0) 
p= 1.000 
Age start physio (months), median 
(IQRa) 
4.0 
(3.0-6.0) 
6.0 
(2.5-10.5) 
p= 0.563 
Gestation 
- Term (n) 
- Preterm (n) 
- Unknown (n) 
 
7 
0 
0 
 
7 
1 
1 
p= 0.964 
History of TBb (n) 0 1 p= 0.563 
Asthma (n) 1 3 p= 0.392 
Pancreas insufficient (n) 7 9 P= 1.000 
HIVc status 
- Negative (n) 
- Exposed (n) 
- Positive (n) 
- Unknown (n) 
 
6 
1 
0 
0 
 
7 
1 
0 
1 
p= 0.958 
Genotype 
- ∆F508 (n) 
   ∆F508 homozygous 
   ∆F508 unknown 
- 3120 (n) 
   3120/G A homozygous 
   3120/G A heterozygous 
- Unknown (n) 
 
5 
     4 
     1 
0 
     0 
     0 
2 
 
6 
     5 
     1 
3 
     2 
     1 
0 
p= 0.422 
Colonisation/ 
infection 
- St. Aureus (n) 
- MRSAd (n) 
- Pseudomonas (n) 
- None (n) 
 
4 
1 
0 
2 
 
8 
0 
1 
0 
p= 0.797 
aIQR= Interquartile Range; bTB= Tuberculosis; cHIV= Human Immunodeficiency Virus; dMRSA=  Meticillin-Resistent 
Staphylococcus Aureus 
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TABLE 2. PRIMARY OUTCOME MEASURES 
Outcome measure Control Intervention p-value 
Total  Median (IQR) Total  Median (IQR) 
Number of hospitalisations 4 0.0 (0.0-1.0) 2 0.0 (0.0-0.0) 0.791 
Days of hospitalisation 25 0.0 (0.0-7.0) 19 0.0 (0.0-7.0) 0.832 
Number of exacerbations 12 2.0 (1.0-3.0) 10 1.0 (1.0-1.0) 0.290 
Days on antibiotic therapy 264 20.0 (10.0-97.0) 167 10.0 (5.0-15.0) 0.355 
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TABLE 3. THEMES IDENTIFYING THE LIKES AND DISLIKES PER AIRWAY CLEARANCE TECHNIQUE 
Technique Subjective themes per technique 
 Likes Dislikes 
AADa - It works (n=2) 
- Easy (n=1) 
- Active technique (n=1) 
- Difficult technique (n=2):  
didn’t get it right (n=1) 
- Unsure when to stop (n=1) 
- Not easy to distract the child (n=1) 
- Less cough production (n=1) 
- Child tires easily (n=1) 
- Child needs to actively cooperate (n=1 
  ( ) Flutter - It works (n=2) 
- Easy (n=1) 
- Feel the vibration/feel that is does something (n=1) 
- Feels like a duty (n=1) 
- Child vomits after the technique (n=1) 
- Nothing (n=1) 
Percussions - Easy (n=6) 
- It works (n=2) 
- Routine/been doing it from the beginning (n=2) 
- Parent feels what he/she is doing (n=1) 
- Bonding and adaptable (n=1) 
- Cough augmentation (n=1) 
- Sleeps better (n=1) 
- Relaxing (n=1) 
- Nothing (n=6) 
- Time consuming (n=2) 
- Scared to hurt the child (n=2) 
- Feels like a duty (n=1) 
- Needs to convince child (n=2) 
- Painful hands (n=1) 
Vibrations - Effective (n=1) 
- Easy (n=1) 
- Time consuming (n=1) 
- Feels like a duty (n=1) 
- Not sure how to perform technique 
 ACBTb - It works (n=1) 
- Easy to motivate the child (n=1) 
- Feels like a duty (n=1) 
- Nothing (n=1) 
Active play - Active (n=3) 
- Parents are happy when child tires (n=2) 
- Fun (n=1) 
- Gets out frustrations (n=1) 
- No extra effort (n=1) 
- Independent (n=1) 
- Clears secretions (n=1) 
- Keeps child busy (n=1) 
- Parent can see that the child is healthy (n=1) 
- Child can be him/herself (n=1) 
- Nothing (n=5) 
- Needs to observe the child (n=1) 
- Fear of dehydration (n=1 
- Child destroys furniture (n=1) 
Other: blowing water (bubble PEPc) - It works (n=1) - none (n=1) 
aAAD = Assisted Autogenic Drainage; bACBT = Active Cycle of Breathing Technique; cPEP= Positive Expiratory Pressure therapy 
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SUPPLEMENTARY FILE 1. TRAINING OF CAREGIVERS 
 
At baseline, all parents in both groups received one on one education on the disease and the 
importance of regular physiotherapy for airway clearance. Thereafter, the clinic therapist explained 
the principle(s) of the selected technique(s) at a language level deemed appropriate by the 
physiotherapist; the technique(s) were demonstrated and then the parents showed the therapist 
how they would perform the technique. The therapist made corrections to the parent’s handling if 
necessary. The parents were encouraged to ask questions during the entire teaching session and 
afterwards time was given to reflect on the handling and addressing questions. Finally the parents 
were asked to demonstrate the technique without feedback from the physiotherapist to make sure 
they understood it entirely. When the performance was inadequate, the physiotherapist gave more 
feedback to ensure the parents knew how to perform the treatment. Only when an adequate level of 
performance (without feedback) was achieved by the parents, were they included in the study [40-
42]. The training took 15 – 30 minutes, depending on individual needs. The parents were given 
contact information for the physiotherapist if they had any questions or concerns. All training was 
conducted one on one with the parents and the same clinic therapist. 
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SUPPLEMENTARY FILE 2: ADDITIONAL TABLES  
SECONDARY OUTCOME MEASURES FOR THE CONTROL AND INTERVENTION GROUPS, PRESENTED AS MEDIAN AND IQR  
  
Outcome measure Control Intervention Change over time: median 
differences (95%CIa) 
Between groups at 
baseline and end 
Within group from 
baseline to end 
Category Outcome Baseline End Baseline End Control Intervention Baseline End Control Intervention 
CFCSb 
n= 7  control 
n= 9 intervention 
Subjective 8.0  
(7.0-11.0) 
8.0 
(6.0-12.0) 
11.0 
(10.0-12.0) 
8.0  
(6.0-11.0) 
0.0 (-4.2-4.2) -3.0 (-6.0-0.0) p= 0.072 p = 0.832 p= 0.753 p= 0.091 
Objective 6.0  
(6.0-8.0) 
7.0 
(5.0-8.0) 
6.0 
(6.0-7.0) 
6.0 
(5.0-6.0) 
1.0 (-1.9-3.9) 0.0 (-1.3-1.3) p= 1.000 p= 0.341 p= 0.787 p= 0.418 
Total 13.0 
(13.0-19.0) 
14.0 
(11.0-22.0) 
17.0  
(17.0-18.0) 
14.0 
(12.0-16.0) 
1.0 (-5.1-7.1) -3.0 (-6.7-0.7) p= 0.204 p= 0.958 p= 1.000 p= 0.093 
EQ-5D-Yc 
n= 7 control 
n= 9 intervention 
VASd score 91.0 
(90.0-99.0) 
95.0 
(75.0-100.0) 
85.0 
(80.0-95.0) 
92.5 
(90.0-10.00) 
4.0 (-19.6-27.6) 7.5 (-6.4-21.4) p= 0.315 p= 0.721 p= 0.917 p= 0.068 
Anthropometry 
n= 7 control 
n= 9 intervention 
BMIe-for-age z-
score 
0.3 
(-1.0-2.3) 
-0.7 
(-1.4-1.8) 
0.1 
(-0.2-0.4) 
-0.3 
(-0.5-0.1) 
-1.0 (-3.9-1.95) -0.4 (-0.9-0.2) p= 0.751 p= 0.672 p= 0.735 p= 0.139 
Weight-for-age 
z-score 
-1.2 
(-1.5-0.4) 
-1.0 
(-1.5-1.5) 
-1.0 
(-1.1-(-0.5)) 
-0.8 
(-1.4-(-0.1)) 
0.2 (-2.7-3.1) 0.2 (-1.0-1.4) p= 0.832 p= 1.000 p= 0.612 p= 0.767 
Height-for-age 
z-score 
-0.6 
(-1.9-0.2) 
-0.3 
(-1.6-(-0.1)) 
-1.3 
(-1.5-(-0.8)) 
-1.0 
(-1.6-0.2) 
0.3 (-2.-3.2) 0.3 (-1.0-1.6) p= 0.525 p= 0.916 p= 0.237 p= 0.260 
aCI= Confidence Interval; bCFCS = Cystic Fibrosis Clinical Score; cEQ-5D-Y= EuroQol 5 Dimensions Youth version; edAS= Visual Analogue Scale; eBMI = Body Mass Index 
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DURATION AND FREQUENCY OF ACTS USED DURING THE STUDY PERIOD 
Technique Intervention (n=7) Control (n= 7) 
 Frequency Median (IQR a) time per session (minutes)  Frequency Median (IQR a) time per session (minutes)  
AADb Daily (n=3) 
Not daily (n=1) 
7.0 (1.0-15.0) - - 
Flutter Daily 10.0  Daily (n=1) 
3x/w (n=1) 
3.0 (2.0-15.0) 
Percussions Daily (n=1) 
Bidaily (n=1) 
3x/d (n=1) 
Not daily (n=1) 
When sick (n=1) 
10.0 (5.0-16.0) 
 
Daily (n=1) 
Bidaily (n=3) 
3x/w (n=1) 
4-5x/w (n=1) 
When sick (n=1) 
15.0 (5.0-15.0) 
Vibrations Not daily N/Ac Bidaily 2.0 (2.0-2.0) 
ACBTd Not daily N/Ac Daily 1.0 
Active play Daily 105.0 (45.0-180.0) Daily 75.0 (60.0-75.0) 
Other: blowing 
  
 
Bidaily N/Ac - - 
aIQR= Interquartile Range; bAAD = Assisted Autogenic Drainage; c N/A = Not Available; dACBT = Active Cycle of Breathing Technique; ePEP= Positive Expiratory 
Pressure therapy 
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SUPPLEMENTARY FILE 3: FIGURES 
FIGURE LEGEND  
Figure 1. Procedural flow diagram 
Figure 2. Study flow diagram 
Figure 3. Number of participants using various ACTs during the study period 
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Recruitment  • Screening for eligibility through patient’s medical files 
• Completion of recruitment data collection form 
• CFCS score was assessed by the clinic physiotherapist 
• EQ-5D-Y was completed by the parents 
• Lung function tests were performed 
 
    
Randomisation and group allocation  • Participants were randomly assigned to the intervention or 
control group, using a computer-generated list of random 
numbers 
• Sealed, opaque, sequentially numbered envelopes were used to 
conceal group allocation 
• Patient information was de-identified and coded by the use of 
coded computer files and/or coded paper files held in sealed 
envelopes 
 
    
Training of parents  • See supplementary file 1 
 
    
1st follow up visit  • Daily diary submission 
• Lung function tests were performed by the same blinded 
respiratory technologist 
• Seen by physiotherapist and parents were asked to demonstrate 
the physiotherapy technique(s) to ensure they were well 
executed and faulty implementation could be corrected. Parents 
could also ask for more explanation or extra demonstrations 
when necessary  
• Intervention group: completed a questionnaire regarding 
therapy preference  
 
    
Follow up on discretion of physician 
(normally on a quarterly basis) 
 
 • Calendar with stickers submission 
• Lung function tests by the same blinded respiratory technologist 
• Seen by physiotherapist and parents were asked to demonstrate 
the physiotherapy technique(s) to ensure they were well 
executed and faulty implementation could be corrected. Parents 
could also ask for more explanation or extra demonstrations 
when necessary 
• Exacerbations and hospitalizations were recorded in the 
participant case file by the pulmonologist, who was blinded to 
group allocation. During hospitalization, participants received 
routine ACT as per the inpatient physiotherapist’s decision. 
 
    
After 1 year follow up  • Lung function tests were repeated by the same blinded 
respiratory technologist 
• CFCS was re-assessed  
• Parents were asked to complete the EQ-5D-Y again.  
• Interview with the CF clinic’s social worker, who was blinded to 
group allocation 
 
Figure 1. Procedural flow chart 
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 Screened n= 36  
 
 
 
  
 
 
Excluded prior to enrolment, n= 19  
(n= 17 with one exclusion criteria; n= 2 with two 
exclusion criteria) 
Reasons for exclusion: 
- Non-compliance prior to enrolment, n= 
8 
- No consent obtained, n= 6 
- No proven diagnosis of CF, n= 4 
- Younger than one year of age, n=1 
- Surgery in the past six months, n=1 
- Uncontrolled asthma, n=1 
   
 Enrolled and 
randomized, n= 17 
 
 
 
 
 
 
Excluded post enrolment/randomization, n=1 
   
 Analyzed n= 16  
  
 
 
Control group n= 7  Intervention group n= 9 
 
 
 
   
   
0 lost to follow-up  0 lost to follow-up 
 
Figure 2. Study flow diagram 
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Figure 3. Number of participants using various ACTs during the study period 
